Biosimulation refers to simulation of biological processes by means of computer program. Biosimulation technology has wide application in drug discovery and development. It is a predictive tool and used in discovery stage to determine the future outcomes of current experimental trials.

Portland, OR -- (SBWire) -- 09/06/2017 --The report provides in-depth analysis of the different segments for global Biosimulation Market and comprehensively determines the market drivers, major constraints and potential opportunities. Pin-point analysis of leading company profiles and their strategies would be helpful to professionals to gain the competitive intelligence. Complete assessment of past and current market trends would be helpful for future projections.

Drug discovery process involves huge investment and failure of drug molecule in the late phase, results in wastage of efforts and money. Hence, there is necessity to develop a tool that will outlay the future drug molecule during discovery phase. This is the prime reason that drives the growth of global biosimulation market. Further, the growth is supported by high healthcare expenditure, advanced software programs and improved simulation technology. Limited knowledge of biological processes, lack of standard methods for biosimulation and high risk of failure of drugs in biosimulation are the major restrains for global biosimulation market. However, increasing accuracy of the technique and integration with other methods for better predictions would be helpful to minimize these restrains.

Global Biosimulation Market by Application

The global biosimulation market has two broad application categories, namely drug discovery and drug development. Applications in drug discovery includes Lead identification, Lead optimization, Target identification, Target validation; whereas, applications in drug development include, Preclinical testing and clinical trials and Patient validation. Application of pharmacokinetic/pharmacodynamic model (PKPD) in pre-clinical testing would be the most opportunistic area for the growth of drug discovery and drug development process.

Global Biosimulation Market by Geography

Geographically, global biosimulation market is segmented into North America, Europe, Asia and LAMEA. North America commands the global biosimulation market and holds more than half of the share value as compared to total global sale. This growth in North America is significantly driven by off patenting of many drugs and search for new drug moiety. Europe stands next to North America for global biosimulation market where growth is majorly driven by government initiatives. Asia-pacific is emerging market where the growth is driven by increase in number of CRO's.

Competitive Landscape

Global biosimulation market is highly competitive, which is dominated by few big players; whereas, rest of the market is highly fragmented. The leading companies in global biosimulation market include Accelrys inc., Schrodinger, ACD/Labs, LeadScope, Certara, Rhenovia, Archimedes, Genedata and Insilico BioTechnology. Companies are focusing on the strategy of collaborations and partnerships to aid the innovation. Accelrys Inc. has signed a three-year agreement with Pfizer for the use of its modeling and simulation software by Pfizer's researchers worldwide.

High Level Analysis

Market dynamics are focused with market drivers, challenges and opportunities, which would be helpful to understand market behavior. Competitive landscape section explicitly covers key players, collaborations, partnerships and agreements, and it would prove beneficial to understand the niche market trends. Porter's five forces analysis have been used to determine the attractiveness of global biosimulation market. Bargaining power of supplier is high as there is less or no threat of backward integration by buyers. Biosimulation technology reduces the total cost of drug discovery and development for pharmaceutical manufacturers. Hence, there is high demand for simulation software and buyers group is less concentrated, which would be sufficient to decrease the buyers bargaining power. Biosimulation techniques need understanding of biological processes and systems, and it also requires standardization of simulation methodology. Lack of expertise in this field puts the threat from substitute and new entrants on low risk situation.

Early buyers will receive 20% customization on this report

Click to Get Sample